Real-World Health Care Services Utilization Associated With the Management of Patients With Relapsed and Refractory Multiple Myeloma in Spain: The CharisMMa Study

Autores de IDIVAL

• 

  Enrique María Ocio San Miguel

  Autor

  enriquem.ocio@scsalud.es

• 

  Carmen Montes Gaisán

  Autor

  carmenm.montes@scsalud.es

Autores ajenos al IDIVAL

• Bustamante G
• Garzón S
• González E
• Pérez-Persona E
• González-Calle V
• Sirvent M
• Arguiñano JM
• González Y
• Ríos R
• de Miguel D
• Grande M
• Fernández-Nistal A
• Naves A
• Rosiñol L

Abstract

This observational, cross-sectional, multicenter study describes the real-world utilization of health care services in relapsed/refractory multiple myeloma (RRMM) patients in Spain. We included data from 276 patients collected from medical records and during a structured interview. Utilization of health care services- mostly hospitalizations, consultations with specialists and imaging tests-was high, underscoring a significant economic burden for the health care system.Background: Most patients with multiple myeloma (MM) relapse or become refractory, resulting in high health care costs. However, real-world data regarding the utilization of health care services among the relapsed/refractory MM (RRMM) population are scarce.Methods: Observational, cross-sectional, multicenter study of the utilization of health care services by RRMM patients who had relapsed within the previous 6 months in Spain in a real-world setting. Data were collected from the clinical records and dur ing a single str uctured interview and included sociodemographic and clinical characteristics at last relapse, the treatment and health care services nature, and were presented using descriptive statistics.Results: The 276 patients enrolled (53.3% males), with a mean [SD] age of 67.4 [10.5] years, had experienced their most recent relapse a median (IQR) of 1.61 (0.74, 3.14) months before entering the study. Patients lived a median (IQR) of 9.0 (3.0, 30.0) km away from the hospital and visited the hospital a median (IQR) of 3.0 (2.0, 5.0) times/month to receive treatment for their most recent relapse. They spent a median (IQR) of 15.84 (5.0, 42.0) euros/month on transportation. Since their most recent relapse, most patients had been admitted to a hospital unit (n = 155, 56.2%), had required >= 1 diagnostic tests (n = 227, 82.2%), and had consulted the hematologist (n = 270, 97.8%) a mean (SD) of 5.5 (5.4) times. In half of the visits, patients were accompanied by an actively working caregiver (n = 112, 54.4%).Conclusions: RRMM treatments are associated with a high utilization of health care services and pose a significant burden for patients and caregivers.Trial registration number: NCT03188536

Copyright © 2023. Published by Elsevier Inc.

Keywords

• Burden; Cost of illness; Monoclonal gammopathy; Multiple myeloma; Therapy